Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Current Oncology (Toronto, Ont.)|August 28, 2024
A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast CancerSharon F McGee, Mark Clemons, Gregory Pond, et al.Dermatology and Therapy|March 17, 2023
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Barbara Melosky, Sandeep Sehdev, et al.Current Oncology (Toronto, Ont.)|November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast CancerJeffrey Q Cao, Brae Surgeoner, Mita Manna, et al.JNCI Cancer Spectrum|August 14, 2025
REaCT-5G: a randomized trial of bone pain with 5-day-filgrastim vs. pegfilgrastim for neutropenia in breast cancerTerry L Ng, Peter Greenstreet, Carol Stober, et al.The Oncologist|July 2, 2013
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 StudyHeather-Jane Au, Wolfgang Eiermann, Nicholas J Robert, et al.Current Oncology (Toronto, Ont.)|February 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025Sandeep Sehdev, Anil Abraham Joy, Jean-François Boileau, et al.Current Oncology (Toronto, Ont.)|November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic SettingMita Manna, Karen A Gelmon, Jean-François Boileau, et al.Current Oncology (Toronto, Ont.)|April 27, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Aalok Kumar, Katarzyna J Jerzak, Karen A Gelmon, et al.Current Oncology (Toronto, Ont.)|February 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025Katarzyna J Jerzak, Aalok Kumar, Jean-François Boileau, et al.Current Oncology (Toronto, Ont.)|May 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025Christine Simmons, Omar F Khan, Christine Brezden-Masley, et al.Pageof 4